{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T20:36:25Z","timestamp":1774730185558,"version":"3.50.1"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2003,10,1]]},"DOI":"10.1086\/377738","type":"journal-article","created":{"date-parts":[[2003,9,19]],"date-time":"2003-09-19T10:01:01Z","timestamp":1063965661000},"page":"905-911","source":"Crossref","is-referenced-by-count":20,"title":["Serious Adverse Events among Participants in the Centers for Disease Control and Prevention's Anthrax Vaccine and Antimicrobial Availability Program for Persons at Risk for Bioterrorism-Related Inhalational Anthrax"],"prefix":"10.1093","volume":"37","author":[{"given":"Bruce C.","family":"Tierney","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacey W.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura H.","family":"Franzke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Marano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dori B.","family":"Reissman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randy D.","family":"Louchart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joyce A.","family":"Goff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy E.","family":"Rosenstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John L.","family":"Sever","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael M.","family":"McNeil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2003,10,1]]},"reference":[{"key":"key\n\t\t\t\t20170522111442_ref1","first-page":"1077","article-title":"Update: investigation of bioterrorism-related anthrax\u2014Connecticut, 200","volume":"50","author":"Centers for Disease Control and Prevention","year":"2001","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key\n\t\t\t\t20170522111442_ref2","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.3201\/eid0810.020353","article-title":"Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic finding","volume":"8","author":"Jernigan","year":"2002","journal-title":"Emerg Infect Dis"},{"key":"key\n\t\t\t\t20170522111442_ref3","first-page":"1024","article-title":"Use of anthrax vaccine in response to terrorism: supplemental recommendations of the Advisory Committee on Immunization Practice","volume":"51","author":"Centers for Disease Control and Prevention","year":"2002","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key\n\t\t\t\t20170522111442_ref4","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.281.18.1735","article-title":"Anthrax as a biological weapon: medical and public health managemen","volume":"281","author":"Inglesby","year":"1999","journal-title":"JAMA"},{"issue":"RR-15","key":"key\n\t\t\t\t20170522111442_ref5","first-page":"1","article-title":"Use of anthrax vaccine in the United State","volume":"49","author":"Centers for Disease Control and Prevention","year":"2000","journal-title":"MMWR Recomm Rep"},{"key":"key\n\t\t\t\t20170522111442_ref6","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1017\/S0022172400044272","article-title":"Observations on the prophylaxis of experimental pulmonary anthrax in the monke","volume":"54","author":"Henderson","year":"1956","journal-title":"J Hyg"},{"key":"key\n\t\t\t\t20170522111442_ref7","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1093\/infdis\/167.5.1239","article-title":"Postexposure prophylaxis against experimental inhalation anthra","volume":"167","author":"Friedlander","year":"1993","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170522111442_ref8","volume-title":"Risk assessment of anthrax threat letters","author":"Kournikakis","year":"2001"},{"key":"key\n\t\t\t\t20170522111442_ref9","first-page":"1051","article-title":"Update: adverse events associated with anthrax prophylaxis among postal employees\u2014New Jersey, New York, and the District of Columbia metropolitan area, 200","volume":"50","author":"Centers for Disease Control and Prevention","year":"2001","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key\n\t\t\t\t20170522111442_ref10","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3201\/eid0810.020349","article-title":"Antimicrobial postexposure prophylaxis for anthrax: adverse events and adherenc","volume":"8","author":"Shepard","year":"2002","journal-title":"Emerg Infect Dis"},{"key":"key\n\t\t\t\t20170522111442_ref11","first-page":"1142","article-title":"Notice to readers: Additional options for preventive treatment for persons exposed to inhalational anthra","volume":"50","author":"Centers for Disease Control and Prevention","year":"2001","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key\n\t\t\t\t20170522111442_ref12","article-title":"Expedited safety reporting requirements for human drug and biological product","volume-title":"Federal register","year":"1997"},{"key":"key\n\t\t\t\t20170522111442_ref13","volume-title":"Physicians desk reference"},{"key":"key\n\t\t\t\t20170522111442_ref14","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1086\/515132","article-title":"Safety of long-term therapy with ciprofloxacin: data of controlled clinical trials and revie","volume":"28","author":"Segev","year":"1999","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170522111442_ref15","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2165\/00002018-200022060-00006","article-title":"Fluoroquinolone-induced renal failur","volume":"22","author":"Lomaestro","year":"2000","journal-title":"Drug Saf"},{"key":"key\n\t\t\t\t20170522111442_ref16","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/j.1875-9114.1987.tb04037.x","article-title":"Increased frequency of doxycycline side effect","volume":"7","author":"Bryant","year":"1987","journal-title":"Pharmacotherapy"},{"key":"key\n\t\t\t\t20170522111442_ref17","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/jac\/39.4.499","article-title":"Atypical pneumonia in Nordic countries: aetiology and clinical results of a trial comparing fleroxacin and doxycyclin","volume":"39","author":"Ragnar","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170522111442_ref18","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1001\/archinte.159.2.167","article-title":"Treatment of Q fever endocarditis: comparison of 2 regimens containing doxycycline and ofloxacin or hydroxychloroquin","volume":"159","author":"Raoult","year":"1999","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t20170522111442_ref19","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1708-8305.1998.tb00476.x","article-title":"Doxycycline as first line malarial prophylaxis: how safe is it","volume":"5","author":"Schuhwerk","year":"1998","journal-title":"J Travel Med"},{"key":"key\n\t\t\t\t20170522111442_ref20","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/pds.712","article-title":"Safety of anthrax vaccine: a review by the Anthrax Vaccine Expert Committee (AVEC) of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS). Anthrax Vaccine Expert Committe","volume":"11","author":"Sever","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"key\n\t\t\t\t20170522111442_ref21","doi-asserted-by":"crossref","DOI":"10.21236\/ADA403352","article-title":"Committee to assess the safety and efficacy of anthrax vaccin","volume-title":"The anthrax vaccine: is it safe? Does it work?","author":"Joellenbeck","year":"2002"},{"key":"key\n\t\t\t\t20170522111442_ref22","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/00006454-200103000-00024","article-title":"Ciprofloxacin-induced acute renal failure in a patient with cystic fibrosi","volume":"20","author":"Bald","year":"2001","journal-title":"Pediatr Infect Dis J"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/37\/7\/905\/17349026\/37-7-905.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,3,10]],"date-time":"2018-03-10T05:16:48Z","timestamp":1520659008000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article-lookup\/doi\/10.1086\/377738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,10,1]]},"references-count":22,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2003,10,1]]},"published-print":{"date-parts":[[2003,10,1]]}},"URL":"https:\/\/doi.org\/10.1086\/377738","relation":{},"ISSN":["1537-6591","1058-4838"],"issn-type":[{"value":"1537-6591","type":"electronic"},{"value":"1058-4838","type":"print"}],"subject":[],"published":{"date-parts":[[2003,10,1]]}}}